Eoneren/E+ via Getty Images IGM Biosciences ( NASDAQ: IGMS ) announced a strategic pivot, under which it decided to immediately begin taking steps, including a reduction in force, to minimize its future spending on the research and clinical development of aplitabart and other oncology candidates. Stock down.
Back to Health Page
